Business, energy, technology, markets and global industry news from Business News Today

HPV16

PharmaDeviceNews HPV16
Representative image: Kovina Therapeutics’ HPV16 E6-targeted research explores whether restoring p53 activity could open a new precision treatment pathway for HPV16-driven cancers and precancerous disease.
Pharma & Biotech

Can Kovina Therapeutics turn HPV16 E6 from an undruggable viral protein into a cancer target?

See how Kovina Therapeutics’ HPV16 E6 inhibitors restore p53 in preclinical models and what must happen before human trials.

Read More
Representative image of circular RNA-based in vivo CAR-T research in a biotechnology laboratory, highlighting Therorna’s TI-0032 program and the growing push to make cell therapy more scalable for autoimmune disease treatment.
Pharma & Biotech

Could Therorna’s circRNA in vivo CAR-T platform change autoimmune disease treatment?

CAR-T is powerful but hard to scale. Therorna’s circRNA platform tests whether in vivo engineering can move the field beyond bespoke therapy.

Read More